NEW YORK, NY / ACCESSWIRE / September 20, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Humanigen, Inc. (NASDAQ:HGEN)
Class Period: May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline: October 25, 2022
The HGEN lawsuit alleges Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in HGEN: https://www.kleinstocklaw.com/pslra-1/humanigen-inc-class-action-loss-submission-form?id=31946&from=1
Abbott Laboratories (NYSE:ABT)
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
Lead Plaintiff Deadline: October 31, 2022
According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ('FDA') health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Learn about your recoverable losses in ABT: https://www.kleinstocklaw.com/pslra-1/abt-lawsuit-abbott-laboratories-loss-submission-form?id=31946&from=1
Sema4 Holdings, Corp. (NASDAQ:SMRF)
Class Period: March 14, 2022 - August 15, 2022
Lead Plaintiff Deadline: November 7, 2022
According to the complaint, Sema4 Holdings, Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4's financial results would be adversely affected; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in SMRF: https://www.kleinstocklaw.com/pslra-1/sema4-lawsuit-loss-submission-form?id=31946&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: